ST316 is under clinical development by Sapience Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ST316’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ST316 overview

ST-316 is under development for the treatment of advanced unresectable and metastatic solid tumors including colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, pancreatic adenocarcinoma, melanoma, cholangiocarcinoma, synovial sarcoma and triple negative breast cancer. It is administered through intravenous route and acts by targeting beta catenin. The therapeutic candidate is a new molecular entity being developed based on protein fragment complementation enhanced with a competitive and negative design initiative (PCA-CANDI) platform.

The therapeutic candidate was under development for the treatment of hematological malignancies. 

Sapience Therapeutics overview

Sapience Therapeutics is a clinical-stage biotechnology company that offers peptide-based cancer therapeutics. The company develops products such as ST101, ß-Catenin Antagonist, cJun Antagonist, FoxP3 Antagonist and others. Sapience Therapeutics ST101 products are used in the treatment of breast cancer, melanoma, prostate cancer, GBM, lung cancer and AML. In addition, the company works in partnership with universities to develop pipeline products for the treatment of GBM and cancer. Sapience Therapeutics is headquartered in Tarrytown, New York, the US.

For a complete picture of ST316’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.